

“Advances in Oncology Seminar series”

Miguel Ángel Quintela-Fandino



*Head of Breast Cancer Clinical Research Unit,
CNIO, Madrid*

Title

“How should we address the problem of compensating pathways in the targeted therapy era? Breast cancer as a model”

14th May 2014, 14.00h

**Biodonostia Health Research Institute
Donostia - San Sebastian**

Miguel Ángel Quintela-Fandino CV summary

Miguel Quintela-Fandino was born in 1976 in La Coruña, Spain. He was awarded his MD degree from the Universidad de Navarra and subsequently trained in Madrid as a medical oncologist at the Hospital Universitario 12 de Octubre. He then received his PhD from the Universidad Complutense de Madrid for his research on the impact of micrometastasis in patients with locally advanced high-risk breast cancer. He also obtained a Master's Degree in biostatistics from the Universidad Autónoma de Barcelona.

After finishing his PhD, Miguel joined T. Mak's laboratory at the Ontario Cancer Institute, Canada, as a Postdoctoral Research Fellow for four years. His work focused on phosphoproteomic screening and the mechanisms of invasion and metastasis in breast cancer including cancer metabolism.

He complemented his clinical training through a clinical fellowship in the Drug Development Programme at Princess Margaret Hospital, Canada, working for over two years on the development of several first-in-class, first-in-human drugs. His research focused on re-designing dose-escalation strategies. Based on a pharmacodynamic approach using the RAF/VEGFR/PDGFR inhibitor sorafenib as a benchmark, he developed a methodology to perform individual drug titrations up to an optimal biological dose by measuring the effects of sorafenib on the signal transduction capacity of targeted kinases as opposed to the classic 3+3 approach.

Miguel has received several grants and honours including the ASCO Young Investigator Award and the ASCO Merit Award (twice), among others. He recently returned to Spain to lead the Breast Cancer Clinical Research Unit at the CNIO, supported by an Asociación Española Contra el Cáncer (AECC) – Beca de Retorno grant.

Advances in Oncology Seminar Series

La Comunidad Autónoma Vasca está realizando un indudable avance en Innovación e Investigación en todos los campos. En particular, la Provincia de Guipúzcoa está sentando las bases para ser un área de referencia en el área de la Oncología. Esto ha sido posible gracias a la inversión que los distintos Estamentos e Instituciones están realizando en este campo en los últimos años.

El Hospital Donostia, el Instituto de Investigación Sanitaria Biodonostia , la fundación Onkologikoa junto con la inestimable ayuda de la AECC Guipúzcoa consideran que es necesario seguir dando pasos adelante en el objetivo de ser un referente en investigación y para ello han organizado el Programa “**Advances in Oncology seminar series**”, una serie de seminarios que se realizará de manera mensual en la que va a participar lo más granado de la ciencia y medicina mundial en la lucha contra el cáncer. El objetivo es debatir los avances recientes y dirigir la investigación y tratamientos futuros que ha de realizarse en nuestra comunidad.